Skip to content
Resources > Reports

Navigating Biopharma Policy: 2025 Changes and a Look Ahead

By Sara Mallatt, Director of Healthcare Research and Sean Carmichael
IndustryLife Sciences & Healthcare

Biopharma firms are grappling with a turbulent and complex policy landscape. The threat of 100% tariffs on imported branded drugs have fundamentally altered business strategy for firms, spurring dealmaking with the federal government in exchange for tariff relief. Heightened policy uncertainty is forcing manufacturers to reevaluate pricing and go-to-market strategies, with a severe expected revenue impact.

AlphaSense recently hosted a webinar with Dr. Robert Popovian, Chief Science Policy Officer at the Global Health Living Foundation to discuss these issues and more. This report leverages key insights from Dr. Popovian and those available in AlphaSense to explore the key policy shifts shaping the biopharma ecosystem.

About the Authors

  • Sara Mallatt, Director of Healthcare Research

    Sara has more than 18 years of experience generating sell-side research content across a variety of industries. Prior to joining AlphaSense, Sara held leadership positions at OTR Global, a leading channel research firm, most recently as Director of Healthcare Research. Sara holds a bachelor’s degree in journalism and a master’s in industrial engineering. She works from her home in Missoula, Montana.

  • Sean Carmichael

    Sean is a Business & Finance Editor at AlphaSense, specializing in sector-specific content production. Previously, he spent nearly a decade in various roles across financial services, where he was responsible for equity research and content generation geared toward institutional investors.

Explore more

All articles

APAC Macro Briefing 2026: Risk Meets Opportunity

In this report, we show how resources and workflows available in the AlphaSense platform can help contextualize the APAC macro environment, exploring the key implications for corporate leaders and investors across sectors.
Report
Title slide for "APAC Macro Briefing 2026: Risk Meets Opportunity" with a map of the Asia-Pacific region.

Top AI Use Cases for Private Equity

In this report, discover how private equity teams are leveraging AI to accelerate conviction with speed. With purpose built, AI-driven solutions like AlphaSense, teams are gaining a competitive advantage with custom workflows and unmatched content sets for the most differentiated deal intelligence.
Report
Top AI Use Cases For Private Equity by Barb Tague, Financial Research Leader. Illustration featuring isometric buildings and currency symbols.

AI in Drug Development 2026: From Experimentation to Execution

Learn how AI is reshaping drug development in real time, turning AI execution into a key competitive differentiator.
Report
Presentation slide titled "AI in Drug Development 2026: From Experimentation to Execution" by Sara Mallatt and Sean Carmichael, with line art of laboratory equipment.

Transform intelligence
into advantage

Develop bold strategies, seize opportunities,
and lead with clarity and confidence.